Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CPN1 | P15169 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23826754 | 0.88 | AKR1C3 (0.40) | AKR1C3ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL23826239 | 0.88 | AKR1C3 (0.40) | AKR1C3ALDH1A1NPC1CPN1CPB2 | |
| SCHEMBL10086273 | 0.85 | AKR1C3 (0.46) | AKR1C3 | |
| SCHEMBL3833697 | 0.83 | SLC6A1 (0.42) | ITGB3ITGA2B | |
| SCHEMBL13611685 | 0.82 | AKR1C3 (0.43) | AKR1C3NAMPTALDH1A1NPC1ITGB3 | |
| SCHEMBL3827927 | 0.81 | EPHX2 (0.38) | AKR1C3ALDH1A1 | |
| SCHEMBL26224524 | 0.80 | AKR1C3 (0.43) | AKR1C3NAMPTPOLBALDH1A1NPC1 | |
| SCHEMBL23842029 | 0.80 | EPHX2 (0.47) | AKR1C3NAMPTALDH1A1NPC1 | |
| Acetic Acid SCHEMBL1773173 | 0.80 | ITGB3 (0.40) | CPN1CPB2ITGB3ITGA2B | |
| SCHEMBL1933685 | 0.79 | ALDH1A1 (0.34) | NAMPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105793255-A | Heterocyclic compounds and their use | 无限药品股份有限公司 | 2016-07-20 | — | — | CN | disclosed |
| CN-103476258-A | Novel cyclic azabenzimidazole derivatives useful as antidiabetic agents | MERCK SHARP & DOHME | 2013-12-25 | — | — | CN | disclosed |
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | disclosed |
| CN-1726033-A | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds | PHARMACIA & UPJOHN CO LLC (US) | 2006-01-25 | — | — | CN | disclosed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | disclosed |
| CN-1602195-A | Quinazoline derivatives for the treatment of abnormal cell growth | PFIZER PROD INC (US) | 2005-03-30 | — | — | CN | disclosed |
| EP-1476449-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070732-A1 | FUSED BICYCLIC-N-BRIDGED-HETEROAROMATIC CARBOXAMIDES FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010528-A1 | Thiazoline derivative and use of the same | TBXA2R, F2, F3 | AKR1C3 847/4885NAMPT 2611/4885POLB 3180/4885 |
| US-20030055043-A1 | Substituted azabicyclic moieties for the treatment of disease | CHRNA1, CHRNA7, CHRNA5 | AKR1C3 1729/4885NAMPT 2661/4885POLB 1229/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | AKR1C3 1641/4885NAMPT 2276/4885POLB 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.